Efficacy and Safety of Oral Nalbuphine Extended Release in Prurigo Nodularis: Results of a Phase 2, Randomized, Controlled Trial with an Open Open-Label Extension Phase

Extended Release ◽

Controlled Trial ◽

Extension Phase ◽

Phase 2 ◽

Efficacy And Safety ◽

Open Label ◽

Prurigo Nodularis ◽

Randomized Controlled ◽

Abstract not available.

25853 Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: Results of a phase 2 randomized controlled trial with an open-label extension phase

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2021.06.313 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB72

Author(s):

Elke Weisshaar ◽

Jacek C. Szepietowski ◽

Thomas R. Sciascia ◽

Gil Yosipovitch ◽

Sonja Ständer

Keyword(s):

Extended Release ◽

Controlled Trial ◽

Extension Phase ◽

Phase 2 ◽

Efficacy And Safety ◽

Open Label ◽

Prurigo Nodularis ◽

Randomized Controlled ◽

Efficacy and Safety of Oral Nalbuphine Extended Release in Prurigo Nodularis: Results of a Phase 2 Randomized Controlled Trial with an Open‐Label Extension Phase

Journal of the European Academy of Dermatology and Venereology ◽

10.1111/jdv.17816 ◽

2021 ◽

Author(s):

E. Weisshaar ◽

J. C. Szepietowski ◽

J. D. Bernhard ◽

H. Hait ◽

F. J. Legat ◽

...

Keyword(s):

Extended Release ◽

Controlled Trial ◽

Extension Phase ◽

Phase 2 ◽

Efficacy And Safety ◽

Open Label ◽

Prurigo Nodularis ◽

Randomized Controlled ◽

Long-Term Efficacy and Safety of Zonisamide for Treatment of Parkinsonism in Patients with Dementia with Lewy Bodies: An Open-label Extension of a Phase 3 Randomized Controlled Trial

American Journal of Geriatric Psychiatry ◽

10.1016/j.jagp.2021.07.002 ◽

2021 ◽

Author(s):

Toshinari Odawara ◽

Kazuko Hasegawa ◽

Ritsuko Kajiwara ◽

Hisao Takeuchi ◽

Masaaki Tagawa ◽

...

Keyword(s):

Dementia With Lewy Bodies ◽

Controlled Trial ◽

Lewy Bodies ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Randomized Controlled ◽

FRI0447 Long-Term (156-Week) Efficacy and Safety Profile of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from A Phase III, Randomized, Controlled Trial and Open-Label Extension (Palace 1)

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2016-eular.3256 ◽

2016 ◽

Vol 75 (Suppl 2) ◽

pp. 597.2-598

Author(s):

A. Kavanaugh ◽

D.D. Gladman ◽

J.J. Gomez-Reino ◽

S. Hall ◽

E. Lespessailles ◽

...

Keyword(s):

Controlled Trial ◽

Phase Iii ◽

Efficacy And Safety ◽

Open Label ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

Open Label Extension ◽

Phosphodiesterase 4 Inhibitor

217. Long-Term (104-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension (PALACE 1)

Rheumatology ◽

10.1093/rheumatology/kev089.104 ◽

2015 ◽

Keyword(s):

Controlled Trial ◽

Phase Iii ◽

Efficacy And Safety ◽

Open Label ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

Open Label Extension ◽

Phosphodiesterase 4 Inhibitor

Efficacy and safety of adding evogliptin versus sitagliptin for metformin-treated patients with type 2 diabetes: A 24-week randomized, controlled trial with open label extension

Diabetes Obesity and Metabolism ◽

10.1111/dom.12870 ◽

2017 ◽

Vol 19 (5) ◽

pp. 654-663 ◽

Cited By ~ 11

Author(s):

Sang-Mo Hong ◽

Cheol-Young Park ◽

Dong-Min Hwang ◽

Kyung Ah Han ◽

Chang Beom Lee ◽

...

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Efficacy And Safety ◽

Open Label ◽

Randomized Controlled ◽

SAT0562 Long-Term (104-Week) Efficacy and Safety of Apremilast Monotherapy in Dmard-Naïve Patients with Psoriatic Arthritis: A Phase 3, Randomized, Controlled Trial and Open-Label Extension (Palace 4)

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2015-eular.2896 ◽

2015 ◽

Vol 74 (Suppl 2) ◽

pp. 863.2-864 ◽

Cited By ~ 5

Author(s):

A. Wells ◽

C. Edwards ◽

A. Adebajo ◽

A. Kivitz ◽

P. Bird ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Controlled Trial ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Randomized Controlled ◽

Invited Perspective on the “Long-Term Efficacy and Safety of Zonisamide for Treatment of Parkinsonism in Patients with Dementia with Lewy Bodies: An Open-label Extension of a Phase 3 Randomized Controlled Trial"

American Journal of Geriatric Psychiatry ◽

10.1016/j.jagp.2021.07.017 ◽

2021 ◽

Author(s):

Jared T. Hinkle ◽

Gregory M. Pontone

Keyword(s):

Dementia With Lewy Bodies ◽

Controlled Trial ◽

Lewy Bodies ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Randomized Controlled ◽

POS-462 EFFICACY AND SAFETY OF PREDNISOLONE ON ALTERNATE DAYS MADE DAILY WITH INFECTIONS VERSUS LEVAMISOLE IN FREQUENTLY RELAPSING NEPHROTIC SYNDROME: AN OPEN LABEL RANDOMIZED CONTROLLED TRIAL

Kidney International Reports ◽

10.1016/j.ekir.2021.03.488 ◽

2021 ◽

Vol 6 (4) ◽

pp. S200-S201

Author(s):

A. Sinha ◽

K. Ghanapriya ◽

P. Hari ◽

A. Bagga

Keyword(s):

Nephrotic Syndrome ◽

Controlled Trial ◽

Efficacy And Safety ◽

Open Label ◽

Frequently Relapsing Nephrotic Syndrome ◽

Randomized Controlled

POS-457 EFFICACY AND SAFETY OF RITUXIMAB VERSUS TACROLIMUS IN FREQUENTLY RELAPSING NEPHROTIC SYNDROME: AN OPEN LABEL RANDOMIZED CONTROLLED TRIAL

Kidney International Reports ◽

10.1016/j.ekir.2021.03.483 ◽

2021 ◽

Vol 6 (4) ◽

pp. S198-S199

Author(s):

G. Mathew ◽

A. Sinha ◽

N. Grewal ◽

A. Ahmad ◽

P. Hari ◽

...

Keyword(s):

Nephrotic Syndrome ◽

Controlled Trial ◽

Efficacy And Safety ◽

Open Label ◽

Frequently Relapsing Nephrotic Syndrome ◽

Randomized Controlled